Format

Send to

Choose Destination
Expert Opin Investig Drugs. 2009 Oct;18(10):1549-57. doi: 10.1517/13543780903183528.

Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma.

Author information

1
Stephen E and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.

Abstract

BACKGROUND:

Treatment strategies targeting angiogenesis have revealed promising results in preclinical studies and early clinical trials in patients with glioblastomas.

OBJECTIVE:

This review evaluates the preclinical and clinical data for cediranib (AZD2171), a potent oral inhibitor of the VEGF receptor tyrosine kinase.

METHODS:

We summarize both preclinical and clinical data for cediranib, with a focus on the treatment of glioblastomas.

RESULTS/CONCLUSION:

Cediranib is an effective drug in patients with glioblastoma, acting through inhibition of angiogenesis and normalization of tumor vasculature. Reduction of vasogenic brain edema is a key component of its treatment effect in this patient population. The primary side effects of cediranib include fatigue, diarrhea and hypertension.

PMID:
19671039
PMCID:
PMC2761074
DOI:
10.1517/13543780903183528
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center